

## Clinical Policy: Pituitary Suppressive Agents, LHRH

Reference Number: PHW.PDL.224

Effective Date: 01/01/2020

Last Review Date: 10/2022

[Revision Log](#)

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of PA Health and Wellness® that Luteinizing Hormone-Releasing Hormone Pituitary Suppressive Agents are **medically necessary** when the following criteria are met:

### I. Requirements for Prior Authorization of Pituitary Suppressive Agents, LHRH

#### A. Prescriptions That Require Prior Authorization

All prescriptions for Pituitary Suppressive Agents, LHRH must be prior authorized.

#### B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Pituitary Suppressive Agent, LHRH, the determination of whether the requested prescription is medically necessary will take into account whether the member:

1. Is prescribed the Pituitary Suppressive Agent, LHRH for an indication that is included in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication; **AND**
2. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. Is prescribed a dose and duration of therapy that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
4. Does not have a history of a contraindication to the prescribed medication; **AND**
5. For a diagnosis of central precocious puberty, **all** of the following:
  - a. Is prescribed the Pituitary Suppressive Agent, LHRH by or in consultation with a pediatric endocrinologist;
  - b. Is  $\leq 11$  years of age for females or  $\leq 12$  years of age for males,
  - c. Experienced onset of secondary sexual characteristics earlier than 8 years in females and 9 years in males;

**AND**

6. For an adolescent with gender dysphoria, **both** of the following:
  - a. Is prescribed the Pituitary Suppressive Agent, LHRH by or in consultation with a pediatric endocrinologist, adolescent medicine specialist, or medical provider with experience and/or training in transgender medicine
  - b. Is prescribed the Pituitary Suppressive Agent, LHRH in a manner consistent with the current World Professional Association for Transgender Health standards of care for the health of transsexual, transgender, and gender nonconforming people;

**AND**

7. For an adult with gender dysphoria, **both** of the following:
  - a. Is prescribed the Pituitary Suppressive Agent, LHRH by or in consultation with an endocrinologist or medical provider with experience and/or training in transgender medicine
  - b. Is prescribed the Pituitary Suppressive Agent, LHRH in a manner consistent with current medical literature;

**AND**

8. For a diagnosis of endometriosis, **all** of the following:
  - a. Has **one** of the following:
    - i. A diagnosis of endometriosis confirmed by laparoscopy
    - ii. A diagnosis of endometriosis supported by chart documentation of an adequate work-up that includes the clinical rationale for the diagnosis,
  - b. Has a history of **all** of the following:
    - i. Therapeutic failure, contraindication, or intolerance of non-steroidal anti-inflammatory drugs
    - ii. Therapeutic failure (based on a 3-month trial), contraindication, or intolerance of oral contraceptives,
  - c. Is prescribed the Pituitary Suppressive Agent, LHRH by or in consultation with a gynecologist;

**AND**

9. For preservation of ovarian function, is receiving cancer treatment that is associated with premature ovarian failure (based on NCCN guidelines or peer-reviewed medical literature); **AND**
10. For Oriahnn (elagolix, estradiol, norethindrone; elagolix) and Myfembree (relugolix/estradiol/norethindrone acetate) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women, has a history of therapeutic failure (based on a 3-month trial), contraindication, or intolerance of contraceptives; **AND**
11. For an elagolix-containing agent or Myfembree (relugolix/estradiol/norethindrone acetate), if the member has a history of depression and/or suicidal thoughts or behaviors or is currently receiving treatment for depression and/or suicidal thoughts or behavior, has a behavioral health assessment prior to use; **AND**
12. For a non-preferred Pituitary Suppressive Agent, LHRH, has a history of therapeutic failure, contraindication, or intolerance of the preferred Pituitary Suppressive Agents, LHRH approved or medically accepted for the member's indication; **AND**
13. If a prescription for a Pituitary Suppressive Agent, LHRH is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override.

NOTE: If the member does not meet the clinical review guidelines above but, in the professional judgement of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

**C. Clinical Review Process**

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Pituitary Suppressive Agent, LHRH. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member.

**D. Approval Duration: 6 months**

**E. References**

1. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(9):3132-3154.
2. Schmidt L, Levine R. Psychological Outcomes and Reproductive Issues Among Gender Dysphoric Individuals. Endocrinol Metab Clin N Am. 44(2015)773-785.
3. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism 2011;13:165-232.
4. Medical Assistance Bulletin Number 99-16-11, Subject: Federal Final Rule, Nondiscrimination in Health Programs and Activities” and Implications for Coverage of Services Related to Gender Transition;  
<http://www.dhs.pa.gov/publications/bulletinsearch/bulletinselected/index.htm?bn=99-16-11&o=N&po=OMAP&id=07/18/2016>.
5. Schenken RS, Barbieri RL, Eckler K. Endometriosis: Pathogenesis, clinical features, and diagnosis. UpToDate. Accessed August 22, 2019.
6. Schenken RS, Barbieri RL, Eckler K. Endometriosis: Treatment of pelvic pain. UpToDate. Accessed August 22, 2019.
7. Orilissa [package insert]. North Chicago, IL. AbbVie, Inc. July 2018.
8. Oriahnn [package insert]. North Chicago, IL. AbbVie, Inc. May 2020.
9. National Comprehensive Cancer Network. Adolescent and Young Adult (AYA) Oncology (Version 1.2020).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/aya.pdf](https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf). Accessed July 9, 2020.
10. Kaplowitz P, Block C. Evaluation and referral of children with signs of early puberty. Pediatrics. 2016; 137(1); e20153732. Available at  
<https://pediatrics.aappublications.org/content/pediatrics/early/2015/12/11/peds.2015-3732.full.pdf>
11. Harrington J, Palmert MR. Definition, etiology, and evaluation of precocious puberty. UpToDate. Accessed August 10, 2021.
12. Harrington J, Palmert MR. Treatment of precocious puberty. UpToDate. Accessed August 10, 2021.
13. Myfembree [package insert]. Mississauga, Ontario. Myovant. May 2021.

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021: policy revised according to DHS revisions effective 01/05/2021	11/2020
Q1 2022: policy revised according to DHS revisions effective 01/03/2022	10/2021
Q1 2023: policy revised according to DHS revisions effective 01/09/2023	10/2022